On August 9, Beijing Foreign Affairs Office and Miyun District jointly organized 76 foreign journalists from 66 countries, including Brazil, Russia, Thailand and Saudi Arabia, to go into Miyun Distric...
Recently, Beilu Pharmaceutical received the Drug Registration Certificate for two sizes (0.375mg and 0.75mg) of Pramipexole Dihydrochloride Sustained-release Tablets (Pramipexole) from the National Me...
The company's product, Jiuwei Zhenxin Granules, has been included in the "Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Bipolar Depression...
Recently, the Beijing Municipal Drug Administration and the Beijing Municipal Health Commission issued a notification on "Commending Outstanding Units and Individuals in the Monitoring of Adverse...
Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...
Beijing Beilu Pharmaceutical Co., Ltd invites youto participate in the 2023 World Life Science Conference and Beijing International Life and Health Industry Cross-border ExpoBooth Number: 1B210Exhibit...